- Advancing 바카라사이트 벳페어 sovereignty with Korea's first homegrown quadrivalent meningococcal 바카라사이트 벳페어
- Poised for full-scale entry into the annual KRW 10 billion military procurement market and global markets like PAHO
[by Kang, In Hyo] EYEGENE announced on October 16 the initiation of the domestic Phase 2 clinical trial for ‘EG-MCV4 (development code),’ a quadrivalent meningococcal vaccine candidate developed with domestic technology.
Prior to this, in July 2024, EYEGENE entered into a ‘Meningococcal Quadrivalent Vaccine Development and Exclusive Sales Agreement" with EuBiologics to ensure the successful development and commercialization of EG-MCV4. The company is jointly conducting the development with BMI Korea, which operates a large-scale GMP-certified production facility.
This Phase 2 clinical trial is designed to evaluate the immunogenicity and safety of EG-MCV4 following a single-dose administration in 125 healthy adult participants with no prior history of meningococcal infection. The study will also assess the non-inferiority of EG-MCV4 compared to the reference vaccine, ‘Menveo.’
EG-MCV4 has already demonstrated a favorable safety profile in preclinical studies, exhibiting immunogenicity levels comparable to or exceeding those of Menveo across all targeted serotypes (A, C, W-135, and Y). Based on these promising results, 바카라사이트 벳페어 intends to proceed with consecutive Phase 2 and Phase 3 clinical trials, with the goal of obtaining product approval in Korea by 2027.
At present, all meningococcal 바카라사이트 벳페어s distributed in Korea are 100% imported. According to data from the Korea Health Industry Development Institute (KHIDI), the domestic meningococcal 바카라사이트 벳페어 market is valued at KRW 10 billion (approximately USD 7 million) annually, with a substantial share of this market comprising government procurement programs for enlisted military personnel.
"The successful development of EG-MCV4 will not only help lower procurement costs by substituting imported vaccines but will also represent a significant milestone toward achieving vaccine self-sufficiency, thereby ensuring a stable vaccine supply in times of infectious disease crises," an EYEGENE official stated.
"EG-MCV4 is Korea's first quadrivalent meningococcal vaccine. We plan to substantially reduce costs compared to imported products in order to compete in the domestic Public Procurement Service bidding market. Additionally, by leveraging our proven domestic technology and strong price competitiveness, we aim to strengthen our position in the global vaccine market," the official further commented.
EYEGENE also intends to pursue rapid expansion into global markets following domestic product approval. According to KHIDI data, the global meningococcal 바카라사이트 벳페어 market is projected to grow at a compound annual growth rate (CAGR) of 9.1%, increasing from USD 3 billion (approximately KRW 4 trillion) in 2021 to USD 5.1 billion by 2027.
The Pan American Health Organization (PAHO), an international body operating under the World Health Organization (WHO), together with UNICEF, constitutes the world's largest 바카라사이트 벳페어 procurement organization. Once product approval in Korea is secured, companies become eligible to participate in PAHO-led tenders without the requirement for separate overseas clinical trials. EYEGENE's strategy plan involves initiating participation in bidding processes across Latin American countries through PAHO, subsequently expanding into the private markets of these regions, and progressively entering key Asian markets, including China, Japan, Thailand, Indonesia, and Malaysia.
"EYEGENE CEO Choi Seok-geun, formerly of EuBiologics, successfully entered the international vaccine procurement market by developing the first domestically produced cholera vaccine to obtain WHO prequalification (PQ) approval. His extensive experience and network in global vaccine procurement are expected to greatly strengthen the company's prospects for entry into the PAHO market," an EYEGENE official said.